Artificial intelligence is increasingly reshaping pharmaceutical research by reducing the time required to analyze complex scientific data and supporting faster decision-making across the drug development lifecycle. Clarivate has expanded the AI capabilities of its Cortellis portfolio, introducing new agentic AI workflows designed to help life sciences organizations accelerate drug discovery, improve safety assessments, and strengthen portfolio strategy through embedded AI automation.
As pharmaceutical companies race to bring new therapies to market, the ability to quickly transform scientific data into actionable intelligence has become a competitive advantage. Clarivate has announced an expansion of agentic AI capabilities across its Cortellis portfolio, marking another step in the growing adoption of AI-powered research platforms within the life sciences industry.
Rather than positioning artificial intelligence as a standalone assistant, the latest update embeds agentic AI directly into existing research and development workflows. The objective is to automate repetitive analytical tasks, synthesize large volumes of scientific evidence, and support researchers, regulatory teams, and business leaders in making faster, data-driven decisions throughout the drug development process.
The announcement reflects a broader trend across enterprise AI, where organizations are moving beyond generative AI chat interfaces toward autonomous systems capable of executing multi-step workflows with limited human intervention. In the life sciences sector, these AI agents are increasingly being deployed to navigate complex biomedical datasets, identify drug candidates, evaluate safety risks, and monitor competitive developments.
Clarivate said the enhanced Cortellis Drug Discovery Intelligence platform enables researchers to interact with scientific and clinical intelligence using natural language. Instead of manually reviewing multiple databases and reports, scientists can compare therapeutic targets, evaluate compounds, analyze disease landscapes, and identify promising research opportunities through conversational AI interfaces.
The approach is intended to reduce the amount of time researchers spend gathering and interpreting information, allowing scientific teams to focus on experimental design, hypothesis validation, and strategic decision-making. As pharmaceutical pipelines become increasingly complex, AI-assisted knowledge discovery is emerging as a critical capability for accelerating early-stage R&D.
Beyond drug discovery, Clarivate is also expanding AI capabilities within OFF-X, its safety intelligence solution. The platform introduces multi-agent AI designed to support pharmacovigilance and toxicology teams by identifying potential safety liabilities earlier in the development process. By synthesizing evidence from multiple sources, the system aims to improve consistency in safety evaluations while helping organizations proactively assess potential risks before clinical or commercial deployment.
Drug safety has become an increasingly data-intensive discipline, requiring organizations to continuously monitor clinical findings, regulatory submissions, post-market surveillance data, and scientific literature. Multi-agent AI systems offer the potential to automate portions of these workflows while enabling specialists to focus on high-priority safety decisions that require expert judgment.
Clarivate is also extending agentic AI into competitive intelligence and portfolio management. New workflows within Cortellis Competitive Intelligence are designed to help business development and strategy teams monitor evolving therapeutic markets, evaluate competing drug pipelines, and assess licensing or acquisition opportunities more efficiently.
According to the company, processes that traditionally required weeks of manual research can now be completed in hours by combining trusted proprietary datasets with AI-powered workflow automation. For pharmaceutical companies managing increasingly diverse research portfolios, faster competitive intelligence can directly influence investment priorities and commercialization strategies.
The latest enhancements position Cortellis as more than a scientific information platform. Instead, Clarivate is evolving the solution into an integrated ecosystem where AI agents assist users across multiple stages of the R&D lifecycle—from early drug discovery and target identification to safety monitoring, regulatory planning, and strategic portfolio optimization.
The announcement aligns with broader industry momentum around enterprise AI agents. Major technology companies including Microsoft, Google Cloud, Amazon Web Services (AWS), and Salesforce have introduced agentic AI platforms capable of automating complex business workflows across industries. Within healthcare and life sciences, however, adoption presents unique challenges due to stringent regulatory requirements, data quality standards, and the need for explainable AI outputs.
Clarivate’s strategy differentiates itself by combining proprietary life sciences data, expert curation, and embedded AI within domain-specific workflows rather than offering general-purpose AI capabilities. This reflects a growing market preference for specialized enterprise AI applications trained on trusted industry datasets.
Industry analysts expect AI adoption across pharmaceutical R&D to continue accelerating. According to McKinsey & Company, generative AI could create between $60 billion and $110 billion in annual value for the pharmaceutical and medical product sectors through faster research, improved clinical development, and operational efficiencies. Meanwhile, Gartner predicts that agentic AI will become a foundational capability for enterprise software as organizations increasingly seek autonomous systems capable of executing complex business processes.
For enterprise life sciences organizations, the expansion of Cortellis demonstrates how AI is evolving from an information retrieval tool into an operational decision-support platform. As drug development becomes more data-intensive and competitive pressures continue to increase, AI-powered workflow automation is expected to play an increasingly important role in helping research teams accelerate innovation while improving scientific consistency and regulatory readiness.
Market Landscape
The pharmaceutical industry is rapidly embracing AI to improve productivity across research, clinical development, and commercialization. According to McKinsey & Company, AI could generate up to $110 billion annually for pharmaceutical companies by accelerating drug discovery and optimizing R&D operations. Gartner also identifies agentic AI as one of the next major enterprise technology trends, with organizations increasingly deploying autonomous AI systems capable of orchestrating complex workflows rather than simply generating content.
As competition intensifies among AI platform providers, domain-specific solutions built on trusted scientific datasets are becoming increasingly valuable for regulated industries such as healthcare and life sciences.
Top Insights
- Clarivate has expanded the Cortellis portfolio with agentic AI capabilities that automate drug discovery, safety assessment, and competitive intelligence workflows for life sciences organizations.
- Embedded AI agents help pharmaceutical R&D teams analyze complex scientific evidence through natural language interactions, reducing manual research while accelerating data-driven decision-making.
- New multi-agent capabilities within OFF-X strengthen pharmacovigilance by identifying potential safety risks earlier and improving consistency across regulatory and post-market evaluations.
- AI-powered competitive intelligence transforms weeks of portfolio analysis into actionable insights delivered within hours, supporting faster strategic planning and business development decisions.
- The announcement reflects the growing shift toward enterprise agentic AI platforms that combine proprietary data, workflow automation, and domain expertise to improve productivity in regulated industries.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
